论文部分内容阅读
目的分析在治疗脑血栓过程中使用阿托伐他汀药物对延缓动脉粥样硬化、降低血脂的功效。方法 90例脑血栓患者,采用随机数字表法分成治疗组和对照组,各45例。对照组接受常规治疗,治疗组在对照组基础上增加阿托伐他汀治疗。比较两组治疗效果。结果治疗前两组血清总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、甘油三酯(TG)比较,差异无统计学意义(P>0.05);治疗后治疗组TC、TG、LDL-C、HDL-C水平变化优于对照组(P<0.05)。治疗后,两组颈动脉斑块面积(Smax)以及颈动脉中层厚度(IMT)均减小,与对照组比较,治疗组的IMT及Smax变化较为明显,差异具有统计学意义(t=3.972、2.435,P<0.05)。两组患者无明显肝肾功能下降、肌肉疼痛等不良反应。结论阿托伐他汀可以显著改善脑血栓患者动脉粥样硬化与血脂水平,并且可以对颈动脉斑块产生软化和缩小的作用,有利于患者二级预防,并且该药物无明显的不良反应,值得推广。
Objective To analyze the effect of using atorvastatin on atherosclerosis and lipid lowering in the treatment of cerebral thrombosis. Methods Ninety patients with cerebral thrombosis were randomly divided into treatment group and control group with 45 cases in each group. The control group received routine treatment, and the treatment group added atorvastatin on the basis of the control group. Compare the treatment effect of two groups. Results There was no significant difference in serum total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C) and triglyceride (TG) 0.05). The levels of TC, TG, LDL-C and HDL-C in the treatment group were better than those in the control group after treatment (P <0.05). After treatment, carotid plaque area (IMT) and carotid artery IMT (IMT) in both groups decreased. Compared with the control group, the changes of IMT and Smax in the treatment group were more obvious, the difference was statistically significant (t = 3.972, 2.435, P <0.05). Two groups of patients with no obvious decline in liver and kidney function, muscle pain and other adverse reactions. Conclusions Atorvastatin can significantly improve the level of atherosclerosis and blood lipid in patients with cerebral thrombosis, and can soften and reduce carotid artery plaque, which is beneficial to the secondary prevention of patients. The drug has no obvious adverse reactions and is worthwhile Promotion.